90 results about "Thyroiditis" patented technology

The present invention relates to the discovery, identification and characterization of nucleic acids that encode a novel protein differentially expressed within the TH2 cell subpopulation (hereinafter referred to as STIF). The invention encompasses STIF nucleotides, host cell expression systems, STIF proteins, fusion proteins, polypeptides and peptides, antibodies to the STIF protein, transgenic animals that express a STIF transgene, or recombinant knock-out animals that do not express the STIF protein, and compounds that modulate STIF gene expression or STIF activity that can be used for diagnosis, drug screening, clinical trial monitoring, and / or used to treat STIF based disorders, such as proliferative disorders and T-lymphocyte-related disorders including, but not limited to, chronic inflammatory diseases and disorders, such as Crohn's disease, reactive arthritis, including Lyme disease, insulin-dependent diabetes, organ-specific autoimmunity, including multiple sclerosis, Hashimoto's thyroiditis and Grave's disease, contact dermatitis, psoriasis, graft rejection, graft versus host disease, sarcoidosis, atopic conditions, such as asthma and allergy, including allergic rhinitis, gastrointestinal allergies, including food allergies, eosinophilia, conjunctivitis, glomerular nephritis, certain pathogen susceptibilities such as helminthic (e.g., leishmaniasis) and certain viral infections, including HIV, and bacterial infections, including tuberculosis and lepromatous leprosy.

The present invention provides a method of treating or preventing a disease or condition in a patient comprising intravenously administering a therapeutically effective amount of mesenchymal stem cells to the patient, wherein the disease or condition is osteoarthritis, rheumatoid arthritis, multiple sclerosis, stroke, ulcerative colitis, psoriasis, Hashimoto's thyroiditis, atopic dermatitis, allergic rhinitis, chronic obstructive pulmonary disease with bronchial asthma or hearing loss.

A method for the treatment or prevention of autoimmune diseases, allergic or atopic disorders, and graft rejection is provided, comprising inducing the death by apoptosis of a subpopulation of T lymphocytes that is capable of causing such diseases, while leaving substantially unaffected the majority of other T lymphocytes. Cell death is achieved by cycle(s) comprising challenging via immunization these T cells with antigenic substance at short time intervals, or by immunization followed by administering interleukin-2 (IL-2) when these T cells are expressing high levels of IL-2 receptor so as to cause these T cells to undergo apoptosis upon re-immunization with the antigenic peptide or protein. These methods are applicable to the treatment of autoimmune diseases such as, for example, multiple sclerosis, uveitis, arthritis, Type I insulin-dependent diabetes, Hashimoto's thyroiditis, Grave's thyroiditis, autoimmune myocarditis, etc., allergic disorders such as hay fever, extrinsic asthma, or insect bite and sting allergies, food and drug allergies, as well as for the treatment or prevention of graft rejection.

The invention includes processes mainly for the treatment of a inflammatory diseases, such as inflammatory bowel disease, arthritis, atherosclerosis, asthma, allergy, inflammatory kidney disease, circulatory shock, multiple sclerosis, chronic obstructive pulmonary disease, skin inflammation, periodontal disease, psoriasis and T cell-mediated diseases of immunity, including allergic encephalomyelitis, allergic neuritis, transplant allograft rejection, graft versus host disease, myocarditis, thyroiditis, nephritis, systemic lupus erthematosus, and insulin-dependent diabetes mellitus. The processes involve treating a patient with a pharmaceutical composition containing an active ingredient that inhibits the activity of sphingosine kinase.

The present invention relates to certain substituted tricyclic acid derivatives of Formula (I) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer.

The present invention relates to furanopyrimidine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula I. The invention also relates to methods of manufacturing medicaments, which comprise one or more compounds of Formula I.

The invention discloses an aconite extract-containing medicinal composition, a preparation method and application thereof. The aconite extract-containing medicinal composition combines the viscera cold primordial qi theory of the six primordial qi theory of 'Kazak Medicine Introduction' which is a traditional medical theoretical basis, and has a main function of removing cold diseases. The Kazak traditional medicament aconite is selected to prepare an external preparation by mixing with white sal-ammoniac (NH4Cl) in proportion through water extraction and ethanol extraction. The preparation includes a medicinal extract and all other external preparations suitable for clinical cold inflammation prevention and treatment. The medicinal compositions has good effect of external auxiliary treatment on bone tuberculosis, scrofula, thyroiditis, rhinitis, bronchial asthma, lumbar disc hernia, rheumatoid arthritis, femoral head necrosis, hyperplasia of mammary glands, hysteromyoma, benign prostatic hyperplasia, osteocarcinoma, psoriasis and the like particularly, has the function of relieving pains and inflammation and the like. The medicinal composition has the advantages of reasonable formula, accurate curative effect, quick response, no irritation and other toxic or side effects, and convenience for preparation.

The present invention relates to a pharmaceutical composition for preventing or treating thyroid diseases and a food composition for improving thyroid function, comprising an extract from Lonicera caerulea L. car. Edulis fruits as an active ingredient.The composition of the present invention may be useful for preventing or treating thyroid diseases such as hypothyroidism, hyperthyroidism, thyroid nodule, or thyroditis, and improving thyroid function. Since the extract from Lonicera caerulea L. car. Edulis fruits, which is an active ingredient of the present invention, is derived from natural products, there is no concern for side effects such as toxicity compared to synthetic medicine.

The detection of parietal cell autoimmune antibodies comprising an ATP4A D3.2 subdomain binding site can diagnose autoimmune body gastritis and / or pernicious anemia with extraordinary sensitivity and specificity that is far superior to existing commercial assays. Further, the assay has diagnostic applications for use in diagnosing type 1 diabetes, thyroiditis and Addison's disease. As pernicious anemia is typically a disease of the elderly, detection of parietal cell antibodies may precede clinical disease by many years if not decades, thereby allowing the initiation of therapeutic interventions such as vitamin B12 administration to prevent the development of pernicious anemia or immunologic interventions to prevent type 1 diabetes and its complications.

The invention discloses a medicine for treating thyroiditis and a preparation method thereof. Prepared with a certain weight ratio, the medicine of the present invention has the functions of soothing the liver and relieving stagnation, resolving phlegm and resolving stagnation, clearing heart and purging fire, clearing heat and detoxifying, promoting blood circulation and removing stasis, softening hard masses, warming spleen and kidney, nourishing qi and nourishing blood, and is used for the treatment of Thyroiditis, short course of treatment, quick effect, no recurrence after cure.

Provided is a novel JAK3 inhibitor useful as a preventive and / or therapeutic agent for organ transplant rejection, graft versus host disease (GvHD), rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sjogren's syndrome, Behcet's disease, type I diabetes mellitus, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, ulcerative colitis, Crohn's disease, asthma, allergic conjunctivitis, atopic dermatitis, contact dermatitis, urticaria, eczema, psoriasis, allergic conjunctivitis, uveitis, cancer, leukemia, etc. A pyridine-3-carboxyamide derivative represented by general formula (1) or a salt thereof or a solvate thereof are also provided.

The invention belongs to the technical field of traditional Chinese medicines and relates to a traditional Chinese medicinal composition for treating hyperthyroidism by employing the traditional Chinese medicines as raw materials. The traditional Chinese medicinal composition is prepared from the following crude medicines by weight: 5-20g of fructus gardeniae praeparatus, 3-15g of pangolin, 5-20g of a turtle shell, 10-30g of codonopsis pilosula, 8-30g of roasted rhizoma atractylodis macrocephalae, 10-30g of dried radix rehmanniae, 10-40g of astragalus membranaceus, 5-30g of angelica sinensis, 5-20g of radix bupleuri, 5-20g of rhizoma cyperi, 5-20g of radix curcumae, 5-20g of fritillary bulb, 10-30g of selfheal, 5-20g of rhizoma sparganii, 5-20g of curcuma zedoary, 3-15g of felwort, 5-25g of raspberries, 10-40g of semen plantaginis, 15-40g of spina date seeds, 5-40g of parched white peony roots, 5-25g of rhizoma atractylodis, 3-15g of honey-fried liquorice, 5-40g of coix seeds, 5-25g of glossy privet fruits and 3-20g of cortex albiziae. The traditional Chinese medicinal composition is capable of effectively treating thyroid gland dysfunction caused by autoimmune thyroiditis and treating both symptoms and root causes, is significant in curative effect, has a pure traditional Chinese medicine formula, and is free of a side effect, safe and reliable.

The invention relates to a medication for treating thyroiditis, which is prepared by taking Chinese herbs as raw materials. The medication is prepared from southernwood, wizened scutellariae, cortex moutan, weeping forsythia, isatis root, ptunella vulgaris, picria fel-terrae, balloonflower root and zhebeinine and can be prepared into various common clinical medicine preparations. Proved by clinical test results, the medication has the advantages of definite effect, no toxic and side effect and safe and reliable clinical application.

It was observed that a highly purified preparation of polar glycolipids extracted from cells of the cyanobacterium Oscillatoria Planktothrix is characterized by the presence of at least one species of high molecular weight glycolipid comprising one or more units of rhamnose. In such mixture, having a level of nucleic acid contamination lower than (or equal to) 3%, an inhibitory activity toward ATP synthase (ATP-SX) was identified which is capable of decreasing the level of extracellular ATP and thereby the extent of the inflammatory response. The glycolipid mixture is especially useful in inflammation induced by ischemic stimuli, cancer or autoimmune diseases (such as multiple sclerosis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis, rheumatoid arthritis, diabetes, autoimmune thyroiditis, systemic lupus erythematosus), in addition to systemic inflammatory states such as systemic inflammatory syndrome (SIRS), sepsis, vasculitis, or in localized inflammatory states, such as neurodegenerative diseases or asthma.

The present invention is related to a method, system or process for screening, studying and treating disorders which have a component of mercurial including: autism, autism spectrum disorders, ADD, ADHD, mental retardation, Asperger's syndrome, childhood psychoses, stammering, stuttering, tics, repetitive movements, eating disorders, sleep disorders, enuresis, disturbances of emotion, developmental language disorders, developmental speech disorders, developmental delay, Alzheimer's disease, diabetes, heart disease, obesity, ALS, nephritic syndrome, renal failure, asthma, systemic lupus, autoimmune thyroiditis, rheumatoid arthritis, arthritis, vasculitis, myelitis, glomerulonephritis, optic neuritis, infantile cerebral palsy, epilepsy, migraine, toxic encephalopathy, polyneuropathy, cerebral degenerations, anterior horn cell disease, spinocerebellar disease, extrapyramidal disease, and myopathy, and other related disorders. The invention of a method of screening, studying and treating of these disorders by utilizing the interaction of mercurial with the steroidgenesis pathway and its control by the hypothalamus-pituitary-adrenal axis is described.

Hashimoto's Thyroiditis (HT) is the most common type of inflammation of the thyroid gland and accurate diagnosis of HT would be advantageous in predicting thyroid failure. The application presents a three tier architecture for image-based diagnosis and a monitoring application using a network cloud. The presentation layer is run on the tablet (e.g., a mobile device), while the business and persistence layers run on a single network cloud or distributed on different network clouds in a multi-tenancy and multi-user application. Such three tier architecture is used for automated data mining application for diagnosis of Hashimoto's Thyroiditis (HT) Disease using ultrasound.

The invention discloses a traditional Chinese medicine for treating thyroiditis and a preparing method thereof. The traditional Chinese medicine is prepared from, by weight, 15-25 parts of honeysuckle, 10-17 parts of solidago, 9-21 parts of blumea riparia, 3-12 parts of radix cynanchi bungei, 5-11 parts of resina toxicodendri, 9-14 parts of ricepaper pith, 3-8 parts of Indian adenosma, 5-10 parts of symplocos lancifolia, 10-17 parts of common gendarussa herb, 5-10 parts of caulis clematidis armandii, 3-9 parts of gentian, 2-7 parts of semen euphorbiae pulveratum, 1-8 parts of senecio scandens, 2-8 parts of radix berberidis, 11-16 parts of trichosanthes kirilowii maxim, and 6-19 parts of cape jasmine. According to the traditional Chinese medicine, raw materials are easy to obtain, cost is low, and treatment effect is remarkable; furthermore, purely natural crude drugs are matched, and side effects, dependency and drug resistance are avoided; treatment course is short, and the traditional Chinese medicine becomes effective quickly, has a good treatment effect and can be widely applied to prevention, control and treatment of thyroiditis.

The present invention provides methods of treating antibody-mediated pathologies, such as autoimmune diseases (eg, SLE, ITP, and thyroiditis), by ameliorating one or more symptoms of the antibody-mediated pathology using agents that inhibit CD21 / C3d interaction. The invention also provides methods for delaying the development of antibody-mediated lesions using agents that inhibit CD21 / C3d interaction.

The invention discloses a traditional Chinese medicine composition for treating Hashimoto's thyroiditis as well as a preparation method and application of the traditional Chinese medicine composition.The traditional Chinese medicine composition is prepared from the following components in parts by weight: 6 to 15 parts of radix bupleuri, 6 to 20 parts of rhizoma cyperi, 6 to 30 parts of radix scutellariae, 10 to 20 parts of herba epimedii, 10 to 30 parts of radix curcumae, 10 to 30 parts of rhizoma bolbostemmae, 6 to 15 parts of airpotato yam rhizome, 6 to 15 parts of rhizoma curcumae, 10 to30 parts of shells of fructus trichosanthis, 6 to 15 parts of semen citri reticulatae, 6 to 15 parts of ginger processed rhizoma pinelliae, 6 to 15 parts of rumex japonicus, 6 to 15 parts of fiveleafakebia fruit, 3 to 9 parts of spanishneedles herb, 6 to 30 parts of roasted malt, 6 to 12 parts of galium aparine, 6 to 15 parts of rhizoma campylandra chinensis, and 10 to 30 parts of herba oldenlandiae diffusae. All herbs are combined to produce a synergistic effect and to play an efficacy for promoting the circulation of qi, reducing the phlegm, invigorating the circulation of blood, removing the stasis, clearing away the internal heat, eliminating the toxicity, warming Yang, and invigorating the spleen. The traditional Chinese medicine composition has the advantages of accurate formula, definite curative effect, simplicity, good effect and the like. The clinical observation shows that the traditional Chinese medicine composition has the effect for reducing thyroid associated antibodies, adjusting the thyroid function and improving the thyroid nodule and is suitable for the clinical popularization and application.

The invention relates to a traditional Chinese medicine for treating autoimmune thyroiditis, which is characterized in that the traditional Chinese medicine is prepared from the following Chinese medicinal materials by mass: 250 to 300 grams of Chinese thorowax root, 150 to 170 grams of thunberg fritillary bulb, 250 to 300 grams of Indian buead, 150 to 170 grams of Chinese angelica and 150 to 170 grams of zedoary. The traditional Chinese medicine is a Chinese medicinal compound preparation for treating the autoimmune thyroiditis, and has the characteristics of soothing the liver and invigorating blood circulation, reducing phlegm and softening hard lumps and dispelling nodes.

Pharmaceutical compositions are provided that are useful in treating immunological diseases. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of a gene related to an immunological disease. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of immunological disease. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl); the gene is one of glucocorticoid-induced leucine zipper, collagen type I alpha 1, and complement component 6; and the immunological disease is Graves' disease, Hashimoto's thyroiditis, autoimmune polyglandular syndrome, insulin-dependent diabetes mellitus, insulin-independent diabetes mellitus, immune-mediated infertility, autoimmune Addison's disease, pemphigus vulgaris, pemphigus foliaceus, dermatitis herpetiformus, vitiligo, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, pernicious anemia, myasthenia gravis, multiple sclerosis, Guillain-Barre syndrome, stiff-man syndrome, acute rheumatic fever, sympathetic ophthalmia, Goodpasture's syndrome, systemic lupus erythematosus, rheumatoid arthritis, systemic necrotizing vasculitis, Wegener's granulomatosis, antiphospholipid syndrome, Sjögren's syndrome, scleroderma, accelerated graft arteriosclerosis, graft-versus-host disease, Crohn's disease, or tuberculosis.

The invention discloses medicinal medicine for treating thyroiditis. The medicinal medicine are prepared from 2-7 parts of burdock, 2-7 parts of bupleurum chinense, 2-7 parts of ligusticum wallichii, 7-15 parts of oldenlandia diffusa, 7-12 parts of seaweed, 7-15 parts of sculellaria barbata, 7-15 parts of trichosanthes palmate, 12-25 parts of honeysuckle flower, 7-15 parts of fructus forsythia, 12-25 parts of kelp, 12-25 parts of selfheal, 10-20 parts of bryozoatum, 20-35 parts of dandelion, 10-20 parts of corydalis bungeana, 7-15 parts of frankincense, 1-3 parts of borneol, and 15-30 parts of oyster in manners of crushing and packaging. The medicinal medicine have the advantages of being available in materials, low in cost, significant in curative effect and the like.

The invention discloses a traditional Chinese medicine for treating thyroiditis. The traditional Chinese medicine is prepared from the following raw materials in percentage by weight: 10%-20% of radix scutellariae, 12%-20% of blackberrylily rhizome, 12%-20% of lotus leaves, 20%-30% of sea-tangle, 10%-20% of radix paeoniae rubra, 20%-30% of flos chrysanthemi, 8%-16% of rhizoma zedoariae, 5%-12% of pinellia ternata, 10%-20% of cortex moutan, 10%-20% of southernwood, 15%-25% of radix isatidis, 10%-20% of folium isatidis, 6%-13% of burdock and 10%-20% of moutan bark. According to the traditional Chinese medicine for treating thyroiditis, sea-tangle and flos chrysanthemi are taken as main drugs, other adjuvants are matched, and the main drugs and the adjuvants are influenced mutually and are synergistic, so that very good effects of enriching the primordial qi, soothing the liver and resolving depression, promoting blood circulation and resolving phlegm as well as eliminating goiter and reducing stagnation are achieved. The traditional Chinese medicine disclosed by the invention has very good treatment effects on a thyroiditis patient and a female patient especially, and is safe without side effect, simple in preparation method and convenient to take.

The invention relates to a medicine for treating deficiency syndrome, its preparing process and usage, wherein the medicine is prepared from fleece-flower root, root of red rooted saliva, Ligusticum wallichii, wolferry fruit, pipe-fish, long-nosed pit viper through the conventional process.

The present invention relates to the field of salt soda water processing and specifically discloses low salt type lemon flavored salt soda water. In a preparation of the salt soda water, the following raw material ingredients are used: soft white sugar, a salicornia europaea extract, edible salt, edible essence, citric acids, an amino acid additive, sodium citrate, sorbitol, vitamins, carbon dioxide and the balanced being purified water. The edible salt is not singly used and the salicornia europaea extract is used to replace a part of sodium chloride, so that a problem that traditional salt soda water is bitter and salty, and does not quench thirsty is solved. The contained trace elements of calcium, potassium, magnesium, ferrum, iodine, etc., enzymes, fibers, alkaloid ingredients, etc. have significant effects on cancers, sinusitis, arthritis, high blood pressure, low blood pressure, low back pain, obesity, hemorrhoids, diabetes, thyroiditis, asthma and bronchitis and the salt soda water is in a low salt type and has a lemon flavor.

The invention relates to a medicament for injection, in particular to an injection medicament for treating chronic lymphoid thyreoitis. The medicament is prepared by mixing methylprednisolone sodium succinate for injection, cyclophosphamide for injection and 2 percent lignocaine injection in certain mixing ratio. The medicament is injected locally, and medicinal strength cannot involve the whole body, which is favorable for deferring and protecting other parts of the body against medicament erosion and has small hormone irritability.

The Chinese patented medicine for treating cholecystitis is prepared with fresh pig bile. The preparation process includes following steps: heating fresh pig bile inside enamel container in slow fire to become ropy while stirring to eliminate bubbles; cooling the container in water at 5-15 deg.c to solidify the ropy pig bile into solid; grinding solidified pig bile into powder and 200-mesh sieving; and capsulizing the pig bile powder in 0.32-0.38 g each. The Chinese patented medicine is used for treating cholecystitis, pancreatitis, thyroiditis, mastitis and toothache effectively and has no side effect and bad reaction.

The invention discloses a traditional Chinese medicine cataplasma for treating autoimmune thyroiditis, and a preparation method of the traditional Chinese medicine cataplasma. The effective components of the traditional Chinese medicine cataplasma are prepared from the following raw materials in parts by weight: 45-55 parts of thunberg fritillary bulb, 15-25 parts of Chinese yam, 5-10 parts of radix isatidis, 8-15 parts of albizia flower and 5-10 parts of acaudina molpadioides. The invention further discloses a preparation method of the traditional Chinese medicine cataplasma. An experiment result proves that the traditional Chinese medicine cataplasma disclosed by the invention has a good treatment effect on the autoimmune thyroiditis, is good in transdermal absorption effect, has the advantages of rapidly releasing medicines and rapidly playing medicine effects, and has good clinical application value; and metabolism of the medicine in gastrointestinal tracts can be avoided.

The invention relates to a traditional Chinese medicine for treating autoimmune thyroiditis, which is characterized in that the traditional Chinese medicine is prepared from the following Chinese medicinal materials by mass: 250 to 300 grams of Chinese thorowax root, 150 to 170 grams of thunberg fritillary bulb, 250 to 300 grams of Indian buead, 150 to 170 grams of Chinese angelica and 150 to 170 grams of zedoary. The traditional Chinese medicine is a Chinese medicinal compound preparation for treating the autoimmune thyroiditis, and has the characteristics of soothing the liver and invigorating blood circulation, reducing phlegm and softening hard lumps and dispelling nodes.